Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $129M | $211M | $25.4M |
| Revenue growth | — | — | — | — | 63.4% | -87.9% |
| Operating income | -$26.7M | -$51.1M | -$97.2M | -$3.16M | $47.0M | -$158M |
| Operating margin | — | — | — | -2.5% | 22.3% | -621.1% |
| Net income | -$26.5M | -$51.2M | -$94.6M | -$6.68M | $65.6M | -$144M |
| Net margin | — | — | — | -5.2% | 31.1% | -565.5% |
| EPS (diluted) | -$24.00 | -$8.16 | -$3.02 | -$0.20 | $1.68 | -$3.47 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$50.9M | -$93.8M | $140M | -$41.6M | -$129M |
| Capital expenditures | $2.32M | $4.58M | $2.89M | $5.61M | $3.16M | $1.04M |
| Free cash flow | -$27.9M | -$55.4M | -$96.7M | $134M | -$44.7M | -$130M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.0M | $291M | $45.2M | $67.6M | $101M | $90.4M |
| Total assets | $43.5M | $306M | $252M | $469M | $526M | $377M |
| Total liabilities | $3.36M | $7.12M | $39.5M | $227M | $97.6M | $71.2M |
| Shareholders' equity | -$41.5M | $299M | $213M | $242M | $429M | $306M |
| Retained earnings | -$42.5M | -$93.7M | -$188M | -$195M | -$129M | -$273M |
| Shares (wtd avg diluted) | 1.11M | 6.27M | 31.3M | 33.1M | 39.0M | 41.4M |
Every figure is extracted from Entrada Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.